English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

A total of 7,860 community-acquired Moraxella catarrhalis isolates (SENTRY Antimicrobial Surveillance Program, 1997 to 2004) were tested by broth microdilution methods, and 399 randomly selected strains from North American sites were tested for BRO-1 and BRO-2 by PCR methods. Several antimicrobials remained very active, including amoxicillin-clavulanate (MIC90s, &lt; or =0.25 microg/ml), azithromycin (MIC90s, &lt; or =0.12 microg/ml), ceftriaxone (MIC90s, 0.5 microg/ml), and levofloxacin (MIC90s, &lt; or =0.03 to 0.06 microg/ml). The BRO-2 incidence rates by year were 3 to 4% overall (96 to 97% for BRO-1) and were the highest in Canada (7.9%), with the incidence in the United States being only 2.0%.

journal of clinical microbiology

Contemporary Prevalence of BRO β-Lactamases in <i>Moraxella catarrhalis</i> : Report from the SENTRY Antimicrobial Surveillance Program (North America, 1997 to 2004)

Contemporary Prevalence of BRO β-Lactamases in Moraxella catarrhalis : Report from the SENTRY Antimicrobial Surveillance Program (North America, 1997 to 2004)